secwatch.observer — SEC 8-K summary
======================================

Issuer:     MAIA Biotechnology, Inc. (MAIA)
CIK:        0001878313
Form:       8-K
Filed at:   2025-10-23T23:59:59+00:00
Accession:  0001493152-25-019014
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MAIA reports 30-month (912-day) survival for a Phase 2 NSCLC patient; ESMO posters presented
--------------------------------------------------------------------------------

- One third-line NSCLC patient on ateganosine (THIO) survived 30 months/912 days as of Sep 17, 2025.
- THIO-101 Phase 2 trial evaluates ateganosine + cemiplimab in checkpoint-inhibitor-resistant advanced NSCLC.
- New Phase 3 THIO-104 trial compares ateganosine+ICI vs chemotherapy in ICI-resistant NSCLC.
- Posters presented at ESMO 2025 in Berlin; full posters available on MAIA website.
- CEO states >2-year survival is a clear signal of ateganosine's efficacy in eliminating NSCLC tumors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225019014/0001493152-25-019014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1878313/000149315225019014/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-019014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer